Unity Biotechnology vs Deciduous Therapeutics

Unity Biotechnology was the marquee publicly traded senolytics company; after its lead eye drug failed and it was delisted from Nasdaq, its board approved a plan of dissolution in 2025.

Longevity

Deciduous Therapeutics

San Francisco biotech developing drugs that activate iNKT immune cells to clear senescent cells from the body.

For subscribers

Subscribe for the full comparison

Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.

Already subscribed? Sign in →